Fundraising Fox
Hemab Therapeutics
NASDAQ: COAGIncorporated in Delaware · 7 known investors
Find your way into Hemab Therapeutics
Sign up to find every way you can get introduced to Hemab Therapeutics
- Your email: who you already know at Hemab Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Hemab Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. The company uses biologics and precision-designed therapeutic candidates to stabilize coagulation proteins and prevent bleeding events.
Investors · 7
How we know: Access Biotechnology's portfolio page · Not right? Tell us
How we know: Avoro Capital Advisors's portfolio page · funding news · Not right? Tell us
How we know: HealthCap's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Novo Holdings's portfolio page · the S-1 prospectus · Not right? Tell us
How we know: Sofinnova Partners's portfolio page · funding news · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
How we know: the S-1 prospectus · Not right? Tell us
Funding
SEC filings, press & company announcements$157M disclosed across 1 of 4 rounds · 1900–2025
- $157MSeries COct 2025 · 2 sourcesSource ↗
Source: company announcements and press reports — follow each round's link for the claim.
Valuation · disclosed
Disclosed eventsSource: SEC prospectus filings, and round valuations the company or its investors disclosed — follow each entry's link for the claim.
Related companies · 2
Companies working in the same space as Hemab Therapeutics.
In the news
Frequently asked questions
- What does Hemab Therapeutics do?
- Hemab develops targeted therapies for bleeding and clotting disorders such as Glanzmann thrombasthenia, Factor VII deficiency, Von Willebrand Disease, and heavy menstrual bleeding. The company uses biologics and precision-designed therapeutic candidates to stabilize coagulation proteins and prevent bleeding events.
- Who are Hemab Therapeutics's investors?
- Hemab Therapeutics's investors include Access Biotechnology, Avoro Capital Advisors, HealthCap, Novo Holdings, Sofinnova Partners, Avoro Ventures, RA Capital.
- How much funding has Hemab Therapeutics raised?
- Hemab Therapeutics has disclosed $157M raised across 1 of its 4 known rounds.